Crystec Chairman and Co-founder, Prof. Peter York, will be speaking at the 4th Annual & Inhaled & Nasal Biologics | DNA Forum 2025, hosted by Intertek. The forum will take place at Hinxton Hall, Cambridge, UK from 25-26 September.
His talk title is “Latest advances in Supercritical Anti-Solvent technology for the inhaled delivery of biotherapeutics”. This conference features two days of talks from leaders in this complex and rapidly expanding area of drug development. The importance of biologic and nucleotide based therapies have increased in recent years, with Crystec’s mSAS® technology being at the forefront of innovation in this area.
Read more about the conference here.
About Professor Peter York: Professor Peter York is the Chairman and a co-founder of CrystecPharma and is also the Chief Scientist with responsibility for guiding the overall science and innovation strategy of the company. He is an Emeritus Professor of Physical Pharmaceutics and a world-leading expert in pharmaceutical materials science. He has published over 300 scientific articles, holds numerous patents, and has received several research awards. He was the founder of Bradford Particle Design Ltd, a spin-out venture from the University of Bradford, based on research and patents in particle formation by supercritical fluids, which was acquired for $200m by Inhale Therapeutics in 2001. He holds Fellowships of the Royal Pharmaceutical Society of Great Britain, the Royal Society of Chemistry, and the American Association of Pharmaceutical Scientists. He sits on MHRA and EMEA drug review panels and is a former member of the British Pharmacopoeia Commission. He is an Honorary Visiting Professor of the Shanghai Institute of Materia Medica, Chinese Academy of Science.